1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. Jama 2006; 295: 2164-2167.
2.
Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003; 27: 1559-1564.
3.
Kim TY, Kim WB, Rhee YS, Song J, Kim M, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006; 65: 364-368.
4.
Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009; 146: 1215-1223.
5.
Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer 2014; 14: 1-13.
6.
Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2015; 10: 99-109.
7.
Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
8.
Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 2014; 46: 509-517.
9.
Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metabol 2013; 98: E1414-E1421.
10.
Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36: 844-850.
11.
Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14: 455-467.
12.
Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ. BRAF as a therapeutic target: a patent review (2006–2012). Expert Opin Ther Pat 2013; 23: 155-164.
13.
Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012; 97: E1745-E1749.
14.
Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-4397.
15.
Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006; 106: 1286-1295.
16.
Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008; 21: S37-S43.
17.
Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 2005; 446: 589-595.
18.
Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013; 44: 2563- 2570.
19.
Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Modica DDC, Turrini L, et al. Immunohistochemistry for BRAF(V600E) antibody VE1 per- formed in core needle biopsy samples identifies mutated papillary thyroid cancers. Horm Metab Res 2014; 46: 370-374.
20.
Martinuzzi C, Pastorino L, Andreotti V, Garuti A, Minuto M, Fiocca R, et al. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. Endocrine 2016; 53: 672-680.
21.
Parker KG, White MG, Cipriani NA. Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis. Head Neck Pathol 2020; 14: 1067-1079.
22.
Bullock M, O’Neill C, Chou A, Clarkson A, Dodds T, Toon C, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012; 19: 779-784.
23.
Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014; 24: 858-866.
24.
Kim YH, Choi SE, Yoon SO, et al. (2014) A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Hum Pathol 45(7):1483-1488. doi:10.1016/j. humpath.2014.02.025
25.
Moskaluk CA, Kern SE. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 1997; 150:1547-1552.
26.
Jung YY, Yoo JH, Park ES, Kyung Kim M, Lee TJ, Cho BY, et al. Clinicopathologic correlations of the BRAF(V600E) mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathol Res Pract 2015; 211: 162-170.
27.
Rossi ED, Martini M, Capodimonti S, Cenci T, Straccia P, Angrisani B, et al. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience. Cancer Cytopathol 2014; 122: 527-535.
28.
Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery 2013; 154: 1199-1204.
29.
Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, et al. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Archiv 2015; 467: 155-168.
30.
Kim HS, Kim JO, Lee DH, Lee HC, Kim HJ, Kim JH, et al. Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. Oncol Rep 2011; 25: 1639-1644.
31.
Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, et al. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery 2017; 161: 1122-1128.
